ストックスクリーナーアプリを入手
0.8105
4.58%
0.0355
前日終値:
$0.775
開ける：
$0.795
24時間の取引高:
575.88K
Relative Volume:
0.39
時価総額：
$96.74M
収益：
-
当期純損益:
$-25.91M
株価収益率:
-3.2201
EPS:
-0.2517
ネットキャッシュフロー:
$-22.73M
1週間 パフォーマンス:
+2.32%
1か月 パフォーマンス:
-9.85%
6か月 パフォーマンス:
-9.94%
1年 パフォーマンス:
-8.22%
1日の値動き範囲:
$0.78
$0.82
1週間の範囲:
$0.7301
$0.82
52週間の値動き範囲:
$0.7301
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
名前
Oncolytics Biotech Inc
セクター
電話
(403) 670-7377
住所
SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, AB
Compare ONCY vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.8105 | 95.50M | 0 | -25.91M | -22.73M | -0.2517 |
VRTX
Vertex Pharmaceuticals Inc
|
478.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
760.66 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
844.50 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.46 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
323.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | 開始されました | Lake Street | Buy |
| 2022-10-06 | 開始されました | Maxim Group | Buy |
| 2021-02-17 | 開始されました | H.C. Wainwright | Buy |
Oncolytics Biotech Inc (ONCY) 最新ニュース
Oncolytics Biotech Inc (ONCY) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Weekly Recap: Pelareorep FDA Fast Track and Nasdaq sub-$1 notice - TradingView
Oncolytics Biotech Inc (ONCY) Balance Sheet - TradingKey
Oncolytics Biotech Inc (ONCY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oncolytics Biotech Inc (ONCY) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oncolytics Biotech Inc (ONCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.810|Chg%:-0.002 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.812|Chg%:-0.036 - TradingKey
ONCY|Oncolytics Biotech Inc|Price:0.784|Chg%:-0.016 - TradingKey
Oncolytics Biotech Inc. (ONCY) Files 8-K Notice of Nasdaq Delisting or Listing Rule Deficiency – July 2026 - Minichart
Oncolytics Biotech Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
ONCY Q2'26 Earnings: revenue estimate is 0 USD - TradingView
ONCY Stock Heads For Sixth Straight Session Of Gains – Lead Therapy Shines in Early Combination Treatment Study - Stocktwits
Oncolytics Biotech Inc (ONCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oncolytics (ONCY) Receives FDA Fast Track Designation for Pelare - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Viral Immunotherapy Gets FDA Fast Track for Anal Cancer Patients Without Options - Tech Times
Oncolytics wins US FDA Fast Track for pelareorep in anal cancer - AllSci
FDA grants fast track status to Oncolytics’ anal cancer therapy By Investing.com - Investing.com South Africa
Oncolytics Biotech Gets US FDA Fast Track Designation for Pelareorep Combination in Anal Cancer Treatment - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Oncolytics receives FDA Fast Track for pelareorep plus checkpoint inhibitor in second-line+ anal cancer - TradingView
FDA grants fast track status to Oncolytics’ anal cancer therapy - Investing.com
Investigational anal cancer therapy posts 30% response rate - Stock Titan
Daily Brief Health Care: First Wave BioPharma , NeuroSpectrum Insights, Mesoblast Ltd, Know Labs , Zoetis Inc, CTT Pharmaceutical Holdings, Oncolytics Biotech, ATAI Life Sciences NV and more - Smartkarma
ONCY: Seeking Registration Pathway for Part B of REO 033 Trial - Smartkarma
MSN Money - MSN
Oncolytics Biotech (ONCY) Edges Lower Amid Light Trading – Key Levels in FocusSign of Weakness - dars.gov.et
Oncolytics Biotech Shares Rise on FDA Meeting Plan, Trial Progress in Colorectal Cancer - Moomoo
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating on trial progress By Investing.com - Investing.com South Africa
Oncolytics advances colorectal cancer trial, plans FDA meeting - Investing.com UK
Oncolytics Biotech shares climb ahead of planned FDA meeting on REO 033 trial (ONCY) - MSN
Oncolytics advances colorectal cancer trial, plans FDA meeting By Investing.com - Investing.com South Africa
Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY) - Yahoo Finance
Oncolytics (ONCY) Updates on REO 033 Clinical Study Progress - GuruFocus
Oncolytics Biotech stock jumps on FDA meeting plans for trial By Investing.com - Investing.com Canada
Oncolytics Biotech stock jumps on FDA meeting plans for trial - Investing.com
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial - The Manila Times
Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer - Quiver Quantitative
ONCY News | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
Oncolytics Biotech Inc (ONCY) Institutional Confidence - TradingKey
Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1%What's Next? - MarketBeat
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Oncolytics Biotech Inc. Replaces Ernst & Young with Baker Tilly as Independent Auditor in 2026 Corporate Restructuring – Minichart - Minichart
Oncolytics Biotech (ONCY) replaces Ernst & Young with Baker Tilly as 2026 auditor - Stock Titan
NMAD Stock Price and Chart — NASDAQ:NMAD - TradingView
Oncolytics Biotech Inc (ONCY) 財務データ
収益
当期純利益
現金流量
EPS
Oncolytics Biotech Inc (ONCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kelly Jared | Chief Executive Officer |
Mar 12 '26 |
Buy |
0.96 |
5,050 |
4,848 |
114,050 |
| Kelly Jared | Chief Executive Officer |
Feb 12 '26 |
Buy |
0.84 |
29,500 |
24,839 |
109,000 |
| Kelly Jared | Chief Executive Officer |
Feb 11 '26 |
Buy |
0.84 |
5,600 |
4,682 |
79,500 |
| Look Kirk | Chief Financial Officer |
Feb 12 '26 |
Buy |
0.84 |
12,000 |
10,104 |
287,515 |
| Pisano Wayne | Director |
Feb 12 '26 |
Buy |
0.84 |
30,000 |
25,338 |
492,414 |
| Heineman Thomas Charles | Chief Medical Officer |
Feb 12 '26 |
Buy |
0.83 |
12,132 |
10,033 |
282,818 |
| Brown Deborah Margaret | Director |
Feb 12 '26 |
Buy |
0.85 |
25,000 |
21,240 |
109,851 |
| Hagerman Allison | VP, Product Development |
Feb 12 '26 |
Buy |
0.83 |
10,000 |
8,298 |
115,059 |
| Seizinger Bernd R. | Director |
Feb 11 '26 |
Buy |
0.83 |
60,000 |
49,590 |
526,991 |
| Seizinger Bernd R. | Director |
Feb 12 '26 |
Buy |
0.85 |
40,000 |
33,864 |
566,991 |
0.98%
1.83%
大文字化:
|
ボリューム (24 時間):